Thermo Fisher Scientific | TMO - Ebitda


Thermo Fisher Scientific reported $3.55B in EBITDA for its fiscal quarter ending in June of 2026.





Ebitda Change Date
Abbott USD 2.43B 844M Mar/2026
Agilent USD 456M 84M Dec/2025
Becton, Dickinson and Co. USD 1.71B 1B Jun/2026
Bio Techne USD 115.94M 763K Jun/2026
Bio-Rad Laboratories USD 595.3M 1.23B Jun/2026
Boston Scientific USD 1.63B 27M Jun/2026
Bruker USD 143.2M 33.2M Jun/2026
Charles River Laboratories USD 272.95M 43.14M Jun/2026
Danaher USD 1.84B 81M Jun/2026
Dentsply International USD 190M 61M Jun/2026
Edwards Lifesciences USD 555.6M 485.5M Mar/2026
General Electric Aerospace USD 3.06B 219M Jun/2026
Henry Schein USD 288M 1000K Jun/2026
Illumina USD 330M 80M Jun/2026
Intuitive Surgical USD 1.06B 29.9M Mar/2026
IQVIA Holdings USD 994M 62M Jun/2026
Laboratory Of America USD 767.7M 162.1M Jun/2026
Medtronic USD 2.81B 119M Mar/2026
Mettler Toledo International USD 322.64M 43.66M Jun/2026
Myriad Genetics USD 14.3M 4M Dec/2025
Olympus JPY 46.26B 2.85B Jun/2026
OraSure Technologies USD -17.7M 4.06M Dec/2025
Quest Diagnostics USD 648M 91M Jun/2026
Repligen USD 43.77M 3.76M Jun/2026
Revvity USD 228.18M 44.73M Jun/2026
Stryker USD 1.93B 357M Jun/2026
Thermo Fisher Scientific USD 3.55B 845M Jun/2026
Veracyte USD 43.96M 1.16M Jun/2026
Waters USD 712M 545M Jun/2026
Zimmer Biomet Holdings USD 830.5M 190.4M Jun/2026